Abstract
Chronic Myelogenous Leukemia (CML) is a myeloproliferative disorder characterized by the presence of Philadelphia chromosome and affects a good number of Africans and African-American population. The aim of this review is to highlight the aetiophysiology, clinical/laboratory characteristics and treatment options, especially the new and emerging treatment modalities of CML. The review was sourced mainly from internet (pubmed). Relevant Oncology journals and textbooks of haematology were also consulted. There are reported cases of relapse/resistance to imatinib which is the current drug of choice in CML treatment. Research has reached advanced stage on the use of alternative drugs (eg Nilotinib and Desatinib) especially in resistant cases. It is hoped that these new drugs will become the treatment of choice and first line drugs for the treatment of CML. We recommend that these new drugs should also be made available and free (just like Imatinib) to resourcepoor African countries like Nigeria.Key words: Chronic Myelogenous Leukemia, Pathophysiology, Treatment
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
